What do systematic reviews say?

26 questions · 26 findings · 4 reviews · Skin

Sort:Best matchNewest Highest certainty Download CSV

No studies found 26 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Subcutaneous biologics (dupilumab) vs placebo

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Oral small molecule inhibitors (ruxolitinib) vs oral small molecule inhibitors (tofacitinib)

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil)

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone) + hair growth stimulants (minoxidil) vs contact immunotherapy (diphencyprone)

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Minoxidil vs placebo

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Other therapies (cryotherapy) vs other therapies (fractional CO2 laser)

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone)

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

NB‐UVB vs PUVA

Health‐related quality of life ‐ not measured · atopic eczema

The review found no eligible studies for this question.

1 finding from 1 review

Phototherapy for atopic eczema 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

UVA1 vs PUVA

Health‐related quality of life ‐ not measured · atopic eczema

The review found no eligible studies for this question.

1 finding from 1 review

Phototherapy for atopic eczema 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

NB‐UVB vs placebo

Health‐related quality of life ‐ not measured · atopic eczema

The review found no eligible studies for this question.

1 finding from 1 review

Phototherapy for atopic eczema 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg

Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ethinyl estradiol 35 μg + cyproterone acetate 2 mg vs ethinyl estradiol 30 μg + desogestrel 0.15 mg

Change in health‐related quality of life (HRQOL) ‐ not measured · patients with hirsutism

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Spironolactone 100 mg vs placebo

Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Finasteride 5 mg to 7.5 mg vs placebo

Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin 500 mg to 2550 mg per day vs placebo

Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Finasteride 5 mg vs spironolactone 100 mg

Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found